Key clinical point: Changes in MRI as soon as 1 month after starting treatment can predict long-term radiographic progression in adults with early rheumatoid arthritis (RA).
Major finding: In a multivariate analyses, synovitis, osteitis, and erosions were assessed using the MRI scoring system RAMRIS (RA MRI scoring system) and RAMRIQ (automated quantitative RA MRI assessment system); RAMRIS measures of erosion change at 1 month (P less than 0.05) and RAMRIQ measures of osteitis change at 1 and 3 months (P less than 0.01 for both) were significant predictors of radiographic progression at 12 months.
Study details: The data come from a post hoc analysis of trial results from 109 adults with an average rheumatoid arthritis duration of 0.7 years.
Disclosures: The study was funded by Pfizer. Five of 11 authors were employees of Pfizer at the time the research was conducted. Three authors declared financial relationships with pharmaceutical companies, including Pfizer.
Conaghan PG et al. Arthritis Res Ther. 2019 Oct 21;21:214. doi: 10.1186/s13075-019-2000-1.